Procept BioRobotics Corp [PRCT] stock is trading at $68.11, up 8.61%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The PRCT shares have gain 1.34% over the last week, with a monthly amount drifted -8.81%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Procept BioRobotics Corp [NASDAQ: PRCT] stock has seen the most recent analyst activity on December 02, 2024, when Morgan Stanley initiated its Overweight rating and assigned the stock a price target of $105. Previously, Jefferies started tracking the stock with Hold rating on November 14, 2024, and set its price target to $95. On August 11, 2023, Piper Sandler initiated with a Overweight rating and assigned a price target of $42 on the stock. William Blair started tracking the stock assigning a Outperform rating. BTIG Research initiated its recommendation with a Neutral. Truist started tracking with a Buy rating for this stock on October 25, 2022, and assigned it a price target of $58. In a note dated September 02, 2022, Wells Fargo initiated an Overweight rating and provided a target price of $49 on this stock.
Procept BioRobotics Corp [PRCT] stock has fluctuated between $45.20 and $103.81 over the past year. Currently, Wall Street analysts expect the stock to reach $105 within the next 12 months. Procept BioRobotics Corp [NASDAQ: PRCT] shares were valued at $68.11 at the most recent close of the market. An investor can expect a potential return of 54.16% based on the average PRCT price forecast.
Analyzing the PRCT fundamentals
Procept BioRobotics Corp [NASDAQ:PRCT] reported sales of 224.50M for the trailing twelve months, which represents a growth of 56.57%. Gross Profit Margin for this corporation currently stands at 0.56% with Operating Profit Margin at -0.53%, Pretax Profit Margin comes in at -0.5%, and Net Profit Margin reading is -0.5%. To continue investigating profitability, this company’s Return on Assets is posted at -0.27, Equity is -0.39 and Total Capital is -0.33. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.33.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 65.43 points at the first support level, and at 62.76 for the second support level. However, for the 1st resistance point, the stock is sitting at 70.79, and for the 2nd resistance point, it is at 73.48.
Ratios To Look Out For
For context, Procept BioRobotics Corp’s Current Ratio is 9.07. In addition, the Quick Ratio stands at 8.01 and the Cash Ratio stands at 3.67. Considering the valuation of this stock, the price to sales ratio is 16.50, the price to book ratio is 14.72.
Transactions by insiders
Recent insider trading involved Zadno Reza, President, CEO, that happened on Dec 04 ’24 when 26423.0 shares were sold. EVP, CLO, CORP. SEC., Nouri Alaleh completed a deal on Dec 04 ’24 to sell 28092.0 shares. Meanwhile, Director REZA ZADNO bought 26423.0 shares on Dec 04 ’24.
